v3.26.1
Significant Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 01, 2026
Sep. 30, 2025
Jun. 30, 2024
Nov. 30, 2022
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaborations revenue         $ 1,200,000 $ 4,000,000  
Accounts receivable         0   $ 305,000
Deferred revenue         300,000 2,500,000  
JSC | Subsequent Event              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Additional exploratory cost reimbursements amount $ 0            
Acuitas License Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
License fee   $ 3,000,000          
Affini-T Therapeutics, Inc. | Development, Option and License Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaborations revenue         0 $ 200,000  
Accounts receivable         0   0
Remaining performance obligation as revenue         0    
Ionis              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Accounts receivable         0   300,000
Deferred revenue         10,900,000   $ 11,700,000
Proceeds from manufactured components         2,500,000    
Ionis | Collaboration and License Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Remaining performance obligation as revenue         15,100,000    
Reimbursable expenses received         6,500,000    
Upfront payment received       $ 80,000,000      
Reimbursement for research costs       10,000,000      
Estimated transaction price       90,000,000      
Collaboration agreement upfront payment received       $ 80,000,000      
Percentage added to cost of goods that represents price of manufactured components       15.00%      
Reimbursable internal costs and out-of-pocket costs payable in quarterly installments       $ 500,000      
Increase in variable consideration     $ 3,400,000        
Ionis | Collaboration and License Agreement | Wave 2 Target              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Potential future target selection fee       15,000,000      
Ionis | Collaboration and License Agreement | Selected Target              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Potential future target selection fee       30,000,000      
Ionis | Collaboration and License Agreement | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Reimbursable internal costs and out-of-pocket costs       10,000,000      
Future development milestone payments to be received         29,000,000    
Future regulatory milestone payments to be received         60,000,000    
Fututre sales-based milestones to be received         $ 250,000,000    
Ionis | Co-Develop and Co-Commercialize Licensed Products              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Exercise fee description         The Co-Co Option exercise fee will equal 50% of Ionis’ internal costs and out-of-pocket costs incurred in the conduct of the drug discovery activities prior to the exercise of the Co-Co Option and be reduced by 50% of the Company’s corresponding costs incurred.    
Cost - share percentage description         The Company may elect to reduce its cost-share percentage anywhere between 50% and 25% on a go-forward basis, provided the Company will continue to bear 50% of the costs of any clinical trials ongoing at the time of the election through the completion of the clinical trials.    
Ionis | Discovery Program              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Revenue       80,000,000      
Ionis | Exploratory Program              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Revenue       $ 10,000,000